# A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion

> **NCT00292760** · PHASE2 · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust**

## Conditions studied

- Chronic Lymphocytic Leukaemia

## Interventions

- **DRUG:** Alemtuzumab
- **DRUG:** Methyprednisolone

## Key facts

- **NCT ID:** NCT00292760
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2009-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00292760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00292760, "A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00292760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*